Dongwha Pharm.Co.,Ltd (000020.KS)
KRW 6360.0
(-1.7%)
KRW 6360.0
(-1.7%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 70.69 Billion KRW | 51.12% |
| 2022 | 46.78 Billion KRW | 29.08% |
| 2021 | 36.24 Billion KRW | -8.25% |
| 2020 | 39.5 Billion KRW | 18.17% |
| 2019 | 33.43 Billion KRW | -23.53% |
| 2018 | 43.71 Billion KRW | 19.43% |
| 2017 | 36.6 Billion KRW | 37.73% |
| 2016 | 26.57 Billion KRW | 1.63% |
| 2015 | 26.15 Billion KRW | -7.86% |
| 2014 | 28.38 Billion KRW | -6.75% |
| 2013 | 30.43 Billion KRW | -3.66% |
| 2012 | 31.59 Billion KRW | -1.77% |
| 2011 | 32.16 Billion KRW | -17.59% |
| 2010 | 39.02 Billion KRW | 4.22% |
| 2009 | 37.44 Billion KRW | -9.49% |
| 2008 | 41.37 Billion KRW | 57.76% |
| 2007 | 26.22 Billion KRW | 48.02% |
| 2006 | 17.71 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 73.19 Billion KRW | 3.98% |
| 2024 Q1 | 70.39 Billion KRW | -0.43% |
| 2023 Q3 | 54.74 Billion KRW | -0.34% |
| 2023 Q4 | 70.69 Billion KRW | 29.14% |
| 2023 Q1 | 49.38 Billion KRW | 5.56% |
| 2023 Q2 | 54.92 Billion KRW | 11.22% |
| 2023 FY | 70.69 Billion KRW | 51.12% |
| 2022 Q3 | 47.06 Billion KRW | 6.84% |
| 2022 Q4 | 46.78 Billion KRW | -0.6% |
| 2022 FY | 46.78 Billion KRW | 29.08% |
| 2022 Q2 | 44.05 Billion KRW | 23.52% |
| 2022 Q1 | 35.66 Billion KRW | -1.59% |
| 2021 Q4 | 36.24 Billion KRW | -13.63% |
| 2021 Q2 | 43.1 Billion KRW | 6.58% |
| 2021 FY | 36.24 Billion KRW | -8.25% |
| 2021 Q3 | 41.96 Billion KRW | -2.66% |
| 2021 Q1 | 40.44 Billion KRW | 2.39% |
| 2020 Q3 | 38.95 Billion KRW | 15.88% |
| 2020 FY | 39.5 Billion KRW | 18.17% |
| 2020 Q1 | 32.63 Billion KRW | -2.37% |
| 2020 Q2 | 33.61 Billion KRW | 3.0% |
| 2020 Q4 | 39.5 Billion KRW | 1.4% |
| 2019 Q4 | 33.43 Billion KRW | -33.13% |
| 2019 FY | 33.43 Billion KRW | -23.53% |
| 2019 Q3 | 49.99 Billion KRW | 1.04% |
| 2019 Q2 | 49.47 Billion KRW | 11.54% |
| 2019 Q1 | 44.36 Billion KRW | 1.47% |
| 2018 Q3 | 42.02 Billion KRW | 0.14% |
| 2018 Q2 | 41.96 Billion KRW | 16.73% |
| 2018 Q1 | 35.95 Billion KRW | -1.78% |
| 2018 FY | 43.71 Billion KRW | 19.43% |
| 2018 Q4 | 43.71 Billion KRW | 4.02% |
| 2017 Q4 | 36.6 Billion KRW | -1.96% |
| 2017 Q3 | 37.33 Billion KRW | 15.19% |
| 2017 Q1 | 28.16 Billion KRW | 5.99% |
| 2017 FY | 36.6 Billion KRW | 37.73% |
| 2017 Q2 | 32.41 Billion KRW | 15.07% |
| 2016 FY | 26.57 Billion KRW | 1.63% |
| 2016 Q2 | 29.35 Billion KRW | 1.24% |
| 2016 Q3 | 28.58 Billion KRW | -2.63% |
| 2016 Q4 | 26.57 Billion KRW | -7.02% |
| 2016 Q1 | 28.99 Billion KRW | 10.88% |
| 2015 Q4 | 26.15 Billion KRW | -13.49% |
| 2015 Q3 | 30.22 Billion KRW | -4.71% |
| 2015 Q2 | 31.72 Billion KRW | 7.65% |
| 2015 Q1 | 29.46 Billion KRW | 3.83% |
| 2015 FY | 26.15 Billion KRW | -7.86% |
| 2014 Q1 | 31.67 Billion KRW | 4.06% |
| 2014 FY | 28.38 Billion KRW | -6.75% |
| 2014 Q4 | 28.38 Billion KRW | -12.17% |
| 2014 Q3 | 32.31 Billion KRW | -1.39% |
| 2014 Q2 | 32.76 Billion KRW | 3.46% |
| 2013 Q4 | 30.43 Billion KRW | -9.08% |
| 2013 FY | 30.43 Billion KRW | -3.66% |
| 2013 Q1 | 34.77 Billion KRW | 10.08% |
| 2013 Q2 | 34.43 Billion KRW | -0.98% |
| 2013 Q3 | 33.47 Billion KRW | -2.8% |
| 2012 Q2 | 32.95 Billion KRW | 5.96% |
| 2012 Q1 | 31.09 Billion KRW | -3.31% |
| 2012 Q4 | 31.59 Billion KRW | -5.01% |
| 2012 FY | 31.59 Billion KRW | -1.77% |
| 2012 Q3 | 33.26 Billion KRW | 0.94% |
| 2011 Q4 | 32.16 Billion KRW | -8.16% |
| 2011 Q1 | 38.13 Billion KRW | -2.28% |
| 2011 FY | 32.16 Billion KRW | -17.59% |
| 2011 Q3 | 35.02 Billion KRW | -5.7% |
| 2011 Q2 | 37.13 Billion KRW | -2.62% |
| 2010 Q3 | 38.95 Billion KRW | -3.67% |
| 2010 FY | 39.02 Billion KRW | 4.22% |
| 2010 Q4 | 39.02 Billion KRW | 0.19% |
| 2010 Q1 | 37.73 Billion KRW | 0.0% |
| 2010 Q2 | 40.43 Billion KRW | 7.16% |
| 2009 Q2 | 38.8 Billion KRW | -6.21% |
| 2009 Q1 | 41.37 Billion KRW | -16.24% |
| 2009 FY | 37.44 Billion KRW | -9.49% |
| 2009 Q3 | 36.02 Billion KRW | -7.14% |
| 2008 Q4 | 49.39 Billion KRW | 29.94% |
| 2008 Q1 | 26.22 Billion KRW | 7.69% |
| 2008 Q2 | 32.26 Billion KRW | 23.02% |
| 2008 FY | 41.37 Billion KRW | 57.76% |
| 2008 Q3 | 38 Billion KRW | 17.82% |
| 2007 FY | 26.22 Billion KRW | 48.02% |
| 2007 Q2 | 17.67 Billion KRW | 0.0% |
| 2007 Q3 | 17.13 Billion KRW | -3.07% |
| 2007 Q4 | 24.35 Billion KRW | 42.12% |
| 2006 FY | 17.71 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -60.122% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 40.012% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 22.453% |
| HANDOK Inc. | 94.46 Billion KRW | 25.16% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -232.801% |
| Yuhan Corporation | 284.75 Billion KRW | 75.173% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 39.218% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -334.827% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 75.522% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -118.308% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -14.536% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -262.977% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -133.476% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -46.228% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -60.122% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -126.298% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -100.979% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -46.893% |
| JW Holdings Corporation | 147.58 Billion KRW | 52.099% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 16.457% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 72.958% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 33.362% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -31.107% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -161.861% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -117.453% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 35.594% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -60.122% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 62.523% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 70.731% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 33.362% |
| Yuhan Corporation | 284.75 Billion KRW | 75.173% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 43.569% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | -14.052% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 72.792% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 33.362% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 11.188% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -43.863% |
| CKD Bio Corp. | 69.08 Billion KRW | -2.338% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 32.719% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -30.78% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -31.107% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 63.701% |
| Boryung Corporation | 189.8 Billion KRW | 62.753% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -24.397% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -14.536% |
| JW Lifescience Corporation | 23.39 Billion KRW | -202.143% |